Exploring the Role of Biosimilars in Optimizing Treatment of Retinal Diseases

The Current Treatment Paradigm in nAMD

Diana Do, MD

Show Description +

Diana Do, MD, reviews the correlation between number of anti-VEGF injections and outcomes in nAMD, as well as the challenges patients face in getting access to treatment.

Posted: 4/14/2023

Keywords:

Neovascular Age-Related Macular Degeneration

•

Anti-VEGF

•

Biogen

Up Next

Name: The Current Treatment Paradigm in nAMD
Uploaded: 2023-04-14T20:48:11+00:00
Description: Diana Do, MD, reviews the correlation between number of anti-VEGF injections and outcomes in nAMD, as well as the challenges patients face in getting access to treatment.

Undertreatment of nAMD and Implications for LongTerm Vision

David Brown, MD; Diana Do, MD; Peter Kaiser, MD; Neal Bressler, MD

What Is a Biosimilar?

Peter Kaiser, MD

Biosimilars: Impact on Cost

Peter Kaiser, MD

Understanding Biosimilar Clinical Trials

Peter Kaiser, MD

Ranibizumab-nuna: Review of Clinical Trial Data

Neil Bressler, MD

A Deeper Look at Clinical Trial Outcomes

David Brown, MD; Diana Do, MD; Peter Kaiser, MD; Neal Bressler, MD

Adopting Bioimilars: Practical Considerations

David Brown, MD

Biosimilars: Health Economic Aspects

David Brown, MD

Biosimilars: Learning from Other Parts of Medicine

Diana Do, MD

What Does the Conversation Sound Like?

David Brown, MD

Back to All Videos

The Current Treatment Paradigm in nAMD

Diana Do, MD

Diana Do, MD, reviews the correlation between number of anti-VEGF injections and outcomes in nAMD, as well as the challenges patients face in getting access to treatment.

Posted: 4/14/2023

Keywords:

Neovascular Age-Related Macular Degeneration

•

Anti-VEGF

•

Biogen

Resources

Biosimilars in Retinal Disease Management

View Resource

About Biogen

One of the world’s first global biotechnology companies, Biogen, was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Biogen is commercializing biosimilars and transforming the standard of care for patients in several areas of high unmet need.

Follow Biogen